| Literature DB >> 33232585 |
Shiri Lea Maymon1, Gil Moravsky1,2, Gil Marcus1,2, Mony Shuvy3, David Pereg1,4, Danny Epstein5, Ilya Litovchik1,2, Shmuel Fuchs1,2, Sa'ar Minha1,2.
Abstract
AIMS: Efforts are constantly made to decrease the rates of readmission after acute decompensated heart failure (ADHF). ADHF admissions to internal medicine departments (IMD) were previously associated with higher risk for readmission compared with those admitted to cardiology departments (CD). It is unknown if the earlier still applies after recent advancement in care over the last decade. This contemporary cohort compares characteristics and outcomes of ADHF patients admitted to IMD with those admitted to CD. METHODS ANDEntities:
Keywords: 30 day readmission; Cardiology; Heart failure; Internal medicine; Mortality; Quality of care
Mesh:
Year: 2020 PMID: 33232585 PMCID: PMC7835581 DOI: 10.1002/ehf2.13084
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Figure 1Study flow diagram. CD, cardiology departments; ICD‐9, International Classification of Diseases 9th Edition; IMD, internal medicine departments.
Baseline demographic, pharmacological, clinical, and laboratory indices of patients admitted with acute decompensated heart failure to internal medicine and cardiology departments
| Index | Internal medicine ( | Cardiology ( |
|
|---|---|---|---|
| Male sex | 3622 (49%) | 586 (67%) | <0.001 |
| Age (median years [IQR]) | 79 [70–86] | 69 [60–78] | <0.001 |
| Heart failure as primary diagnosis | 3333 (45%) | 239 (27%) | <0.001 |
| Medical history | |||
| Myocardial infarction | 61 (0.80%) | 13 (1.50%) | 0.046 |
| Ischaemic heart disease | 3024 (41%) | 326 (37%) | 0.060 |
| Valvular disease | 1039 (14%) | 129 (15%) | 0.514 |
| Anaemia | 1771 (24%) | 104 (12%) | <0.001 |
| Renal failure | 2532 (34%) | 210 (24%) | <0.001 |
| Atrial fibrillation | 2407 (32%) | 163 (19%) | <0.001 |
| Hypertension | 1307 (17%) | 114 (13%) | <0.001 |
| Diabetes mellitus | 3750 (50%) | 405 (46%) | 0.025 |
| COPD | 1234 (16%) | 71 (8%) | <0.001 |
| PVD | 543 (7%) | 59 (7%) | 0.560 |
| Obesity | 1611 (22%) | 144 (16%) | <0.001 |
| Smoking | 1080 (14%) | 247 (28%) | <0.001 |
| Chronic medical therapy | |||
| Alpha‐blockers | 825 (11%) | 68 (8%) | 0.003 |
| Beta‐blockers | 2637 (35%) | 381 (43%) | <0.001 |
| Calcium channel blockers | 1940 (26%) | 179 (20%) | <0.001 |
| ACEi | 1388 (19%) | 180 (21%) | 0.161 |
| ARB | 814 (11%) | 111 (13%) | 0.115 |
| Aldactone | 188 (2%) | 17 (2%) | 0.296 |
| Other heart failure medications | 2 (<0.1%) | 1 (0.10%) | 0.283 |
| Anti‐arrhythmic | 498 (7%) | 68 (8%) | 0.224 |
| Anti‐platelets | 3104 (42%) | 452 (52%) | <0.001 |
| Oral anticoagulant | 1081 (14%) | 98 (11%) | 0.008 |
| Statin | 2860 (38%) | 420 (48%) | <0.001 |
| Other hyperlipidaemic | 143 (2%) | 21 (2%) | 0.331 |
| Digoxin | 351 (5%) | 79 (5%) | 0.658 |
| Diuretics | 3705 (55%) | 878 (55%) | 0.932 |
| Combination pills | 97 (1%) | 17 (1%) | 0.243 |
| Laboratory indices | |||
| Haemoglobin (g/dL ± SD) | 11.6 [10.3–13.0] | 12.7 [11.3–14.1] | <0.001 |
| WBC (K/μL [IQR]) | 10.5 [7.1–12.1] | 11.25 [7.8–13.7] | <0.001 |
| Urea (mg/dL [IQR]) | 64.54 [36.90–77.90] | 52.48 [34.52–62.60] | <0.001 |
| Sodium (mmol/L [IQR]) | 137.36 [135–141] | 137.57 [135–140] | 0.91 |
| Creatinine (mg/dL [IQR]) | 1.47 [0.85–1.57] | 1.29 [0.86–1.42] | 0.074 |
| Echocardiography | |||
| Normal LV function | 1099 (51.60%) | 110 (24.70%) | <0.001 |
| Mild LV dysfunction | 312 (15%) | 72 (16%) | <0.001 |
| Moderate LV dysfunction | 495 (23%) | 157 (39%) | <0.001 |
| Severe LV dysfunction | 223 (10%) | 88 (20%) | <0.001 |
| Total LV dysfunction | 445 (17%) | 2129 (83%) | <0.001 |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; IQR, inter‐quartile range; LV, left ventricular; PVD, peripheral vascular disease; SD, standard deviation; WBC, white blood cell.
In‐hospital procedures and discharge prescriptions of patients admitted with acute decompensated heart failure to internal medicine and cardiology departments
| Index | Internal medicine | Cardiology |
|
|---|---|---|---|
| Procedures performed during hospitalization | |||
| Cardiac stress test | 8 (0.10%) | 10 (1.10%) | <0.001 |
| Nuclear stress test | 1 (<0.1%) | 0 (0%) | >0.999 |
| Diagnostic coronary angiography | 100 (1%) | 102 (12%) | <0.001 |
| Urgent PCI | 32 (0.40%) | 85 (10%) | <0.001 |
| Therapeutic PCI | 52 (0.70%) | 84 (10%) | <0.001 |
| CABG | 62 (0.80%) | 115 (13%) | <0.001 |
| Permanent pacemaker implantation | 66 (0.90%) | 36 (4%) | <0.001 |
| CRTD | 11 (0.10%) | 10 (1%) | <0.001 |
| Dialysis | 106 (1%) | 9 (1%) | 0.346 |
| Discharge drugs | |||
| Alpha‐blockers | 1140 (15%) | 57 (6%) | <0.001 |
| Beta‐blockers | 3997 (54%) | 503 (57%) | 0.029 |
| Calcium channel blockers | 2494 (33%) | 153 (17%) | <0.001 |
| ACEi | 1976 (26%) | 357 (41%) | <0.001 |
| ARB | 1070 (14%) | 112 (13%) | 0.214 |
| Aldactone | 207 (3%) | 13 (1%) | 0.024 |
| Other HF | 2 (0%) | 0 (0%) | >0.999 |
| Anti‐arrhythmic | 651 (9%) | 123 (14) | <0.001 |
| Anti‐platelets | 4316 (56%) | 562 (64%) | <0.001 |
| Oral anticoagulation | 1992 (27%) | 162 (18%) | <0.001 |
| Statin | 4038 (54%) | 562 (64%) | <0.001 |
| Other hyperlipidaemic | 178 (2%) | 14 (1.7%) | 0.142 |
| Digoxin | 337 (4.%) | 34 (4%) | 0.390 |
| Diuretics | 5702 (76%) | 458 (52%) | <0.001 |
| Combination pills | 228 (3%) | 13 (1%) | 0.009 |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; CRTD, cardiac resynchronization therapy/defibrillator; other HF, other heart failure medications; PCI, percutaneous coronary intervention.
Multivariable logistic regression analyses for indices independently associated with 30 day readmission
| Index | Backward stepwise logistic regression model | Forced logistic regression model | ||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% confidence interval |
| Odds ratio | 95% confidence interval |
| |
| Admitting department—cardiology | 0.79 | 0.65–0.97 | 0.023 | 0.79 | 0.65–0.96 | 0.023 |
| Sex | 0.94 | 0.83–1.05 | 0.274 | |||
| Age (years) | 0.99 | 0.99–1.00 | 0.062 | 0.99 | 0.99–1.00 | 0.047 |
| Diabetes mellitus | 1.11 | 0.99–1.25 | 0.061 | 1.12 | 0.99–1.25 | 0.060 |
| Hypertension | 1.01 | 0.94–1.27 | 0.210 | |||
| Ischaemic heart disease | 1.16 | 1.04–1.30 | 0.009 | 1.15 | 1.02–1,28 | 0.017 |
| Chronic obstructive pulmonary disease | 1.14 | 0.99–1.33 | 0.074 | 1.17 | 1.00–1.35 | 0.045 |
| Atrial fibrillation | 1.28 | 1.14–1.44 | <0.01 | 1.31 | 1.17–1.48 | <0.01 |
| Smoking | 1.28 | 1.01–1.49 | 0.002 | 1.26 | 1.08–1.47 | <0.01 |
| Renal failure | 1.20 | 1.07–1.36 | 0.003 | 1.17 | 1.04–1.32 | 0.010 |
| Anaemia | 1.37 | 1.20–1.56 | <0.01 | 1.39 | 1.27–1.58 | <0.01 |
| Valvular disease | 1.23 | 1.05–1.44 | 0.008 | |||
| Alpha‐blockers at admission | 0.83 | 0.69–0.99 | 0.046 | |||
| Other heart failure medications at admission | 8.26 | 0.72–93.9 | 0.089 | |||
| Hospitalization days | 0.52 | 0.99–1.00 | 0.525 | |||
| Obesity | 0.91 | 0.78–1.05 | 0.182 | |||